Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps

Harmsen, Theo; Jongerius, M. C.; Zwan, Cees W Van Der; Plantinga, A. D.; Kraaijeveld, C. A.; Berbers, Guy A. M.

doi:10.1128/jcm.30.8.2139-2144.1992

Cited by 36 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in one of the early clinical trials with the Jeryl Lynn vaccine, antibody titres measured at 4 weeks following the administration of the vaccine were lower than those measured 5 weeks after mumps immunization 21 . Other studies have also noted the slow development of neutralizing antibodies after immunization 22 . The slow reaction of the immune system could be an indication that the current mumps vaccine strains are not as immunogenic as previously thought.…”

Section: Discussionmentioning

confidence: 90%

Detection of mumps virus‐specific memory B cells by transfer of peripheral blood mononuclear cells into immune‐deficient mice

Vandermeulen¹,

Verhoye

Vaidya³

et al. 2010

Immunology

View full text Add to dashboard Cite

Summary Waning immunity to mumps after one or two doses of the measles, mumps and rubella (MMR) vaccine has been described. Using a human peripheral blood lymphocyte (PBL)–severe combined immunodeficiency (SCID) mouse model, MMR vaccine recipients with undetectable and high antibody titres against mumps were compared for the presence of circulating mumps‐specific memory B cells. Peripheral blood mononuclear cells (PBMC) from six donors (three subjects with undetectable and three with high antibody titres against mumps) were injected into the spleens of non‐obese diabetic (NOD)‐SCID mice (three mice per subject). Mice were pretreated with TMβ1 and total body irradiation to improve engraftment. In vivo production of human antibodies against mumps was evaluated in mouse plasma on days 7, 10 and 13 with a commercial enzyme‐linked immunosorbent assay (ELISA), functional reduction neutralization test. Three donors had mumps antibody titres below the detection limit (titre < 230) and three had high antibody titres (range 5700–7300). None of the mice injected with PBMC from subjects with undetectable antibody titres showed detectable human antibody titres, despite the presence of cell‐mediated immunity in two of the three donors. Seven out of nine mice injected with PBMC from subjects with high antibody titres acquired detectable antibody titres for mumps in their plasma. PBMC from vaccinees without detectable serum antibodies against mumps virus were unable to induce secretion of anti‐mumps antibodies in the blood of recipient mice, whereas PBMC from vaccinees with high antibody titres were able to do so. This observation suggests that the frequency of mumps‐specific memory B cells is very low in vaccinees with undetectable antibody titres. These individuals may therefore be at risk of developing mumps disease upon encounter with wild‐type virus.

show abstract

Section: Discussionmentioning

confidence: 90%

Detection of mumps virus‐specific memory B cells by transfer of peripheral blood mononuclear cells into immune‐deficient mice

Vandermeulen¹,

Verhoye

Vaidya³

et al. 2010

Immunology

View full text Add to dashboard Cite

show abstract

“…The vaccines were manufactured by the National Institute of Public Health and the Environment and given at the local municipal health service. When the children were 42 months of age, humoral antibody levels (IgG) in plasma were measured against measles, mumps, and rubella virus with an ELISA, as described previously (11)(12)(13).…”

Section: Subjectsmentioning

confidence: 99%

Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children.

Weisglas‐Kuperus

Patandin

Berbers

et al. 2000

Environ Health Perspect

Self Cite

322

View full text Add to dashboard Cite

Prenatal exposure to polychlorinated biphenyls (PCBs) and dioxins is associated with changes in the T-cell lymphocyte population in healthy Dutch infants. We investigated whether these changes persist into later childhood and whether background exposure to PCBs and dioxins is associated with the prevalence of infectious or allergic diseases and humoral immunity at preschool age. The total study group consisted of 207 healthy mother-infant pairs. We estimated prenatal exposure to PCBs and dioxins by the sum of PCBs 118, 138, 153, and 180 (sigmaPCB) in maternal and cord plasma and in breast-fed infants by the dioxin, planar, and mono-ortho PCB toxic equivalent (TEQ) levels in human milk. At 42 months of age, current body burden was estimated by the PCB in plasma. We assessed the prevalence of infectious and allergic diseases by parent questionnaire, and measured humoral immunity by antibody levels for mumps, measles, and rubella after primary vaccination. We performed immunologic marker analyses of lymphocytes in a subgroup of 85 children. Prenatal PCB exposure was associated with an increased number of lymphocytes, T-cells, and CD3CD8(+) (cytotoxic), CD4(+)CD45RO(+) (memory), T-cell receptor (TcR) [alpha]ss(+), and CD3(+)HLA-DR(+) (activated) T cells and lower antibody levels to mumps and measles at preschool age. Adjusted for confounders, prenatal PCB exposure was associated with less shortness of breath with wheeze, and current PCB body burden was associated with a higher prevalence of recurrent middle-ear infections and of chicken pox and a lower prevalence of allergic reactions. A higher dioxin TEQ was associated with a higher prevalence of coughing, chest congestion, and phlegm. We conclude that in Dutch preschool children the effects of perinatal background exposure to PCBs and dioxins persist into childhood and might be associated with a greater susceptibility to infectious diseases. Common infections acquired early in life may prevent the development of allergy, so PCB exposure might be associated with a lower prevalence of allergic diseases.

show abstract

“…Therefore, they are less suitable for screening large numbers of serum samples. Recently, we have developed neutralization tests based on an enzyme immunoassay for mumps virus, encephalomyocarditis virus, and Semliki Forest virus in cell culture with horseradish peroxidase (HRPO)-labeled virus-specific monoclonal antibodies (MAbs), which can be applied for rapid and objective titration of virus infectivity and virus-neutralizing antibodies (8,(16)(17)(18).…”

mentioning

confidence: 99%

Neutralization enzyme immunoassay for influenza virus

et al. 1994

Self Cite

View full text Add to dashboard Cite

A neutralization enzyme immunoassay (N-EIA) was developed for the detection of antibody titer rises in sera of patients infected with influenza A (H3N2) virus. In this N-EIA, a selected strain of influenza A (H3N2) virus was added to monolayers of LLC-MK2 cells in microtiter plates. After 24 h, the replicated virus could be demonstrated with a virus-specific enzyme-labeled monoclonal antibody. Preincubation of the influenza virus with convalescent-phase sera of patients infected with influenza A (H3N2) virus resulted 1 day later in decreased absorbance values that could be used for calculation of neutralization titers. From use of paired serum samples from 10 patients with a history of flu-like symptoms, the results obtained with N-EIA correlated well (r = 0.83) with those of the standard hemagglutination inhibition test.

show abstract

Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps

Cited by 36 publications

References 13 publications

Detection of mumps virus‐specific memory B cells by transfer of peripheral blood mononuclear cells into immune‐deficient mice

Detection of mumps virus‐specific memory B cells by transfer of peripheral blood mononuclear cells into immune‐deficient mice

Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children.

Neutralization enzyme immunoassay for influenza virus

Contact Info

Product

Resources

About